Grunenthal Acquires Global Rights for Qutenza(R)

Food and Healthcare Press Releases Tuesday November 6, 2018 09:30
AACHEN, Germany--6 Nov--PRNewswire/InfoQuest

Grunenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grunenthal is now the sole owner of Qutenza(R) worldwide, including the US, Latin America, Asia and Australia. Grunenthal had already acquired exclusive commercial rights for Europe, Middle East and Africa in December 2016.

"As a leader in pain research and management, we're dedicated to providing solutions for patients with high unmet medical needs. Qutenza(R) is a perfect strategic fit, as it complements our existing pain portfolio and is a real alternative to the current standard of care," says Gabriel Baertschi, Grunenthal's Chief Executive Officer.

Qutenza(R) is a highly effective pain product. A single, 1-hour, localised treatment with this patch may provide at least 3 months of relief from for example post-shingles nerve pain. Grunenthal will aim to make Qutenza (R) available to patients worldwide. In territories where the company does not have a presence of its own such as Asia and Australia, Grunenthal will look to partner or out-license Qutenza(R).

Grunenthal continues executing its growth strategy and has been expanding its pain portfolio by a series of acquisitions including European rights to Nexium(R), the global (ex US and Japan) rights to Vimovo(R) and global (ex Japan) rights to Zomig(R). The company has signed deals with a total value of more than US$ 1.3 billion since 2016.

About Qutenza(R)

Qutenza(R) (capsaicin) 8% patch is approved in the US for the management of neuropathic pain associated with postherpetic neuralgia. A single, 1-hour, localized treatment with Qutenza(R) may provide at least 3 months of relief from for example post-shingles nerve pain (PHN). In Europe, Qutenza(R) is approved by the European Medicines Agency for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other pain medicines. The 8% capsaicin patch delivers a high dose of capsaicin directly to the damaged nerves in the skin that are the source of neuropathic pain. Applied to the area of pain, the capsaicin reduces the spontaneous activity and consequently reduces the neuropathic pain intensity. Important safety information can be found here: http://www.qutenza.com and http://www.ema.europa.eu/documents/product-information/qutenza-epar-product-information_en.pdf

About Grunenthal

Grunenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a EUR 2 bn company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Grunenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in approx. 30 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 100 countries and approx. 5,200 employees are working for Grunenthal worldwide. In 2017, Grunenthal achieved revenues of approx. EUR 1.3 bn.

More information: http://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Twitter: @grunenthalgroup
Instagram: gruenenthal
For further information, please contact:
Stepan Kracala, Head Global Communications
Tel.: +49-241-569-1335, Stepan.Kracala@grunenthal.com
Grunenthal GmbH, 52099 Aachen, Germany
Kerstin Nacken, Head Editorial Management and Media Relations
Tel.: +49-241-569-2710, Kerstin.Nacken@grunenthal.com
Grunenthal GmbH, 52099 Aachen, Germany
Source: Grunenthal Group

Latest Press Release

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Related Topics